These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23933338)

  • 1. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
    Joshi H; Lewis K; Singharoy A; Ortoleva PJ
    Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
    O'Rourke JP; Peabody DS; Chackerian B
    Curr Opin Virol; 2015 Apr; 11():76-82. PubMed ID: 25829254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.
    Zhang X; Xin L; Li S; Fang M; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2015; 11(5):1277-92. PubMed ID: 25751641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus.
    Yong CY; Yeap SK; Goh ZH; Ho KL; Omar AR; Tan WS
    Appl Environ Microbiol; 2015 Feb; 81(3):882-9. PubMed ID: 25416760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad spectrum assessment of the epitope fluctuation--Immunogenicity hypothesis.
    Grosch JS; Yang J; Shen A; Sereda YV; Ortoleva PJ
    Vaccine; 2015 Nov; 33(44):5945-9. PubMed ID: 26187254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
    Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
    J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
    Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
    Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus.
    Mobini S; Chizari M; Mafakher L; Rismani E; Rismani E
    Front Immunol; 2020; 11():2074. PubMed ID: 33042118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advancements in combination subunit vaccine development.
    Tan M; Jiang X
    Hum Vaccin Immunother; 2017 Jan; 13(1):180-185. PubMed ID: 27649319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles.
    Sun C; Ding FX; Wang F; He XW; He Y; Li ZS; Sun SH
    Microbiol Immunol; 2009 Jun; 53(6):340-8. PubMed ID: 19493202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
    Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
    Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
    Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
    PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particles in picornavirus vaccine development.
    Dong H; Guo HC; Sun SQ
    Appl Microbiol Biotechnol; 2014 May; 98(10):4321-9. PubMed ID: 24647496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
    Hankaniemi MM; Stone VM; Andrejeff T; Heinimäki S; Sioofy-Khojine AB; Marjomäki V; Hyöty H; Blazevic V; Flodström-Tullberg M; Hytönen VP; Laitinen OH
    Antiviral Res; 2019 Nov; 171():104595. PubMed ID: 31491431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV.
    Wang YS; Ouyang W; Liu XJ; He KW; Yu SQ; Zhang HB; Fan HJ; Lu CP
    Vaccine; 2012 Mar; 30(12):2125-30. PubMed ID: 22285269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.